» Articles » PMID: 33415123

Nutritional Interventions in Cancer Cachexia: Evidence and Perspectives From Experimental Models

Overview
Journal Front Nutr
Date 2021 Jan 8
PMID 33415123
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cachexia is a complex metabolic syndrome characterized by involuntary skeletal muscle loss and is associated with poor clinical outcome, decreased survival and negatively influences cancer therapy. No curative treatments are available for cancer cachexia, but nutritional intervention is recommended as a cornerstone of multimodal therapy. Optimal nutritional care is pivotal in the treatment of cancer cachexia, and the effects of nutrients may extend beyond provision of adequate energy uptake, targeting different mechanisms or metabolic pathways that are affected or deregulated by cachexia. The evidence to support this notion derived from nutritional intervention studies in experimental models of cancer cachexia is systematically discussed in this review. Moreover, experimental variables and readout parameters to determine skeletal muscle wasting and cachexia are methodologically evaluated to allow critical comparison of similar studies. Single- and multinutrient intervention studies including qualitative modulation of dietary protein, dietary fat, and supplementation with specific nutrients, such as carnitine and creatine, were reviewed for their efficacy to counteract muscle mass loss and its underlying mechanisms in experimental cancer cachexia. Numerous studies showed favorable effects on impaired protein turnover and related metabolic abnormalities of nutritional supplementation in parallel with a beneficial impact on cancer-induced muscle wasting. The combination of high quality nutrients in a multitargeted, multinutrient approach appears specifically promising, preferentially as a multimodal intervention, although more studies investigating the optimal quantity and combination of nutrients are needed. During the review process, a wide variation in timing, duration, dosing, and route of supplementation, as well as a wide variation in animal models were observed. Better standardization in dietary design, and the development of experimental models that better recapitulate the etiology of human cachexia, will further facilitate successful translation of experimentally-based multinutrient, multimodal interventions into clinical practice.

Citing Articles

Muscle loss in cancer cachexia: what is the basis for nutritional support?.

Faiad J, Andrade M, de Castro G, de Resende J, Coelho M, Aquino G Front Pharmacol. 2025; 16:1519278.

PMID: 40078277 PMC: 11897308. DOI: 10.3389/fphar.2025.1519278.


The treatment interventions and targets of cancer cachexia research during the past decade: a systematic review of the literature.

Filis P, Peschos D, Simos Y, Filis N, Zachariou C, Stagikas D Ann Gastroenterol. 2025; 38(1):85-92.

PMID: 39802285 PMC: 11724389. DOI: 10.20524/aog.2024.0918.


Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.


The dynamics of food for special medical purposes (FSMPs) utilization in cancer care: from doctor recommendations to online pharmacy procurement.

Chereches M, Popa C, Finta H Front Pharmacol. 2024; 15:1393784.

PMID: 39119613 PMC: 11307204. DOI: 10.3389/fphar.2024.1393784.


The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.

Skorzewska M, Geca K Curr Oncol Rep. 2024; 26(11):1334-1348.

PMID: 39110350 PMC: 11579082. DOI: 10.1007/s11912-024-01589-4.


References
1.
Kwiterovich Jr P, Vining E, Pyzik P, Skolasky Jr R, Freeman J . Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA. 2003; 290(7):912-20. DOI: 10.1001/jama.290.7.912. View

2.
Ham D, Murphy K, Chee A, Lynch G, Koopman R . Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr. 2013; 33(3):448-58. DOI: 10.1016/j.clnu.2013.06.013. View

3.
Delage B, Fennell D, Nicholson L, McNeish I, Lemoine N, Crook T . Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010; 126(12):2762-72. DOI: 10.1002/ijc.25202. View

4.
Michaelis K, Zhu X, Burfeind K, Krasnow S, Levasseur P, Morgan T . Establishment and characterization of a novel murine model of pancreatic cancer cachexia. J Cachexia Sarcopenia Muscle. 2017; 8(5):824-838. PMC: 5659050. DOI: 10.1002/jcsm.12225. View

5.
Abramson E, Kukla L, Shevrin D, Lad T, McGuire W, Kukreja S . A model for malignancy-associated humoral hypercalcemia. Calcif Tissue Int. 1984; 36(5):563-7. DOI: 10.1007/BF02405367. View